Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer

Authors: Fuqiang Dai, Lunxu Liu, Guowei Che, Nanbin Yu, Qiang Pu, Shangfu Zhang, Junliang Ma, Lin Ma, Zongbing You

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Tumor microenvironment is composed of tumor cells, fibroblasts, endothelial cells, and infiltrating immune cells. Tumor-associated immune cells may inhibit or promote tumor growth and progression. This study was conducted to determine whether the number and microlocalization of macrophages, mature dendritic cells and cytotoxic T cells in non-small cell lung cancer are associated with patient's survival time.

Methods

Ninety-nine patients with non-small cell lung cancer (NSCLC) were included in this retrospective study. Paraffin-embedded NSCLC specimens and their clinicopathological data including up to 8-year follow-up information were used. Immunohistochemical staining for CD68 (marker for macrophages), CD83 (marker for mature dendritic cells), and CD8 (marker for cytotoxic T cells) was performed and evaluated in a blinded fashion. The numbers of immune cells in tumor islets and stroma, tumor islets, or tumor stroma were counted under a microscope. Correlation of the cell numbers and patient's survival time was analyzed using the Statistical Package for the Social Sciences (version 13.0).

Results

The numbers of macrophages, mature dendritic cells and cytotoxic T cells were significantly more in the tumor stroma than in the tumor islets. The number of macrophages in the tumor islets was positively associated with patient's survival time, whereas the number of macrophages in the tumor stroma was negatively associated with patient's survival time in both univariate and multivariate analyses. The number of mature dendritic cells in the tumor islets and stroma, tumor islets only, or tumor stroma only was positively associated with patient's survival time in a univariate analysis but not in a multivariate analysis. The number of cytotoxic T cells in the tumor islets and stroma was positively associated with patient's survival time in a univariate analysis but not in a multivariate analysis. The number of cytotoxic T cells in the tumor islets only or stroma only was not associated with patient's survival time.

Conclusions

The number of macrophages in the tumor islets or stroma is an independent predictor of survival time in NSCLC patients. Counting macrophages in the tumor islets or stroma is more useful in predicting patient's survival time than counting mature dendritic cells or cytotoxic T cells.
Appendix
Available only for authorised users
Literature
1.
Witz IP, Levy-Nissenbaum O: The tumor microenvironment in the post-PAGET era. Cancer Lett. 2006, 242 (1): 1-10. 10.1016/j.canlet.2005.12.005.CrossRefPubMed
2.
Lin A, Schildknecht A, Nguyen LT, Ohashi PS: Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol Lett. 2009
3.
Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC: Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol. 2005, 23 (5): 953-964. 10.1200/JCO.2005.12.172.CrossRefPubMed
4.
Loose D, Wiele Van de C: The immune system and cancer. Cancer Biother Radiopharm. 2009, 24 (3): 369-376. 10.1089/cbr.2008.0593.CrossRefPubMed
5.
Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest. 1997, 111 (6): 1710-1717. 10.1378/chest.111.6.1710.CrossRefPubMed
6.
Yu N, Pu J, Pu Q, Che G, Zhang S, Liu L: Influence of Tumor Associated Macrophages Distribution on Prognosis of Non-small Cell Lung Cancer. Chin J Clin Thorac Cardiovasc Surg. 2009, 16 (1): 44-47.
7.
Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. 2004, Lyon: IARC Press
8.
Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L: The origin and function of tumor-associated macrophages. Immunol Today. 1992, 13 (7): 265-270. 10.1016/0167-5699(92)90008-U.CrossRefPubMed
9.
Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow?. Lancet. 2001, 357 (9255): 539-545. 10.1016/S0140-6736(00)04046-0.CrossRefPubMed
10.
Chen JJ, Yao PL, Yuan A, Hong TM, Shun CT, Kuo ML, Lee YC, Yang PC: Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 2003, 9 (2): 729-737.PubMed
11.
Toomey D, Smyth G, Condron C, Kelly J, Byrne AM, Kay E, Conroy RM, Broe P, Bouchier-Hayes D: Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up. Int J Cancer. 2003, 103 (3): 408-412. 10.1002/ijc.10836.CrossRefPubMed
12.
Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P: Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. 2005, 23 (35): 8959-8967. 10.1200/JCO.2005.01.4910.CrossRefPubMed
13.
Mantovani A, Sica A, Locati M: Macrophage polarization comes of age. Immunity. 2005, 23 (4): 344-346. 10.1016/j.immuni.2005.10.001.CrossRefPubMed
14.
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23 (11): 549-555. 10.1016/S1471-4906(02)02302-5.CrossRefPubMed
15.
Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P: Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. 2009, 33 (1): 118-126. 10.1183/09031936.00065708.CrossRefPubMed
16.
Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, et al: Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008, 26 (27): 4410-4417. 10.1200/JCO.2007.15.0284.CrossRefPubMed
17.
Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, et al: Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008, 113 (6): 1387-1395. 10.1002/cncr.23712.CrossRefPubMed
18.
Mantovani A, Sica A, Locati M: New vistas on macrophage differentiation and activation. Eur J Immunol. 2007, 37 (1): 14-16. 10.1002/eji.200636910.CrossRefPubMed
19.
Fukui T, Mori S, Yokoi K, Mitsudomi T: Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol. 2006, 1 (2): 120-125. 10.1097/01243894-200602000-00004.CrossRefPubMed
20.
Ueda K, Kaneda Y, Sakano H, Tanaka T, Hayashi M, Li TS, Hamano K: Independent predictive value of the overall number of metastatic N1 and N2 stations in lung cancer. Jpn J Thorac Cardiovasc Surg. 2003, 51 (7): 297-301. 10.1007/BF02719381.CrossRefPubMed
21.
Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes RM, Busund LT: The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology. 2009, 55 (3): 301-312. 10.1111/j.1365-2559.2009.03379.x.CrossRefPubMed
22.
Kim DW, Min HS, Lee KH, Kim YJ, Oh DY, Jeon YK, Lee SH, Im SA, Chung DH, Kim YT, et al: High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer. 2008, 98 (6): 1118-1124. 10.1038/sj.bjc.6604256.CrossRefPubMedPubMedCentral
23.
van Cruijsen H, Ruiz MG, Valk Van der P, de Gruijl TD, Giaccone G: Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer. 2009, 9: 180-10.1186/1471-2407-9-180.CrossRefPubMedPubMedCentral
24.
Bergeron A, El-Hage F, Kambouchner M, Lecossier D, Tazi A: Characterisation of dendritic cell subsets in lung cancer micro-environments. Eur Respir J. 2006, 28 (6): 1170-1177. 10.1183/09031936.06.00114205.CrossRefPubMed
25.
Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H: Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006, 94 (2): 275-280. 10.1038/sj.bjc.6602934.CrossRefPubMedPubMedCentral
26.
Geissmann F, Dieu-Nosjean MC, Dezutter C, Valladeau J, Kayal S, Leborgne M, Brousse N, Saeland S, Davoust J: Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med. 2002, 196 (4): 417-430. 10.1084/jem.20020018.CrossRefPubMedPubMedCentral
27.
Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, de Saint-Vis B, Jacquet C, Yoneda K, Imamura S, Schmitt D, Banchereau J: CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med. 1996, 184 (2): 695-706. 10.1084/jem.184.2.695.CrossRefPubMed
28.
Kretschmer B, Luthje K, Schneider S, Fleischer B, Breloer M: Engagement of CD83 on B cells modulates B cell function in vivo. J Immunol. 2009, 182 (5): 2827-2834. 10.4049/jimmunol.0803153.CrossRefPubMed
29.
Karagoz B, Bilgi O, Gumus M, Erikci AA, Sayan O, Turken O, Kandemir EG, Ozturk A, Yaylaci M: CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med Oncol. 2009
Metadata
Title
The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer
Authors
Fuqiang Dai
Lunxu Liu
Guowei Che
Nanbin Yu
Qiang Pu
Shangfu Zhang
Junliang Ma
Lin Ma
Zongbing You
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-220

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer

Research article

Recurrence and mortality according to Estrogen Receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast

Research article

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia

Research article

Assessment of depression and anxiety in adult cancer outpatients: a cross-sectional study

Research article

Simplifying the detection of MUTYH mutations by high resolution melting analysis

Research article

No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits